Emergent BioSolutions (NYSE:EBS) Now Covered by Benchmark

Research analysts at Benchmark initiated coverage on shares of Emergent BioSolutions (NYSE:EBS) in a report released on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $150.00 price target on the biopharmaceutical company’s stock. Benchmark’s price target would indicate a potential upside of 101.42% from the company’s previous close.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company downgraded Emergent BioSolutions from an “overweight” rating to an “equal weight” rating and set a $110.00 price target on the stock. in a research report on Friday, January 8th. Chardan Capital raised Emergent BioSolutions from a “neutral” rating to a “buy” rating and set a $112.00 price objective on the stock in a research note on Tuesday, March 2nd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $110.57.

NYSE EBS opened at $74.47 on Tuesday. The stock’s 50-day simple moving average is $89.10 and its two-hundred day simple moving average is $95.86. Emergent BioSolutions has a twelve month low of $60.46 and a twelve month high of $137.61. The company has a quick ratio of 2.30, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $3.97 billion, a price-to-earnings ratio of 23.95 and a beta of 1.26.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Wednesday, February 17th. The biopharmaceutical company reported $3.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.72 by $0.95. Emergent BioSolutions had a return on equity of 26.68% and a net margin of 12.50%. The business had revenue of $583.00 million for the quarter, compared to the consensus estimate of $588.39 million. On average, equities analysts expect that Emergent BioSolutions will post 6.94 earnings per share for the current fiscal year.

In related news, Director Sue Bailey sold 8,168 shares of the firm’s stock in a transaction dated Thursday, March 4th. The stock was sold at an average price of $92.37, for a total value of $754,478.16. Following the sale, the director now directly owns 24,427 shares of the company’s stock, valued at $2,256,321.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert Kramer sold 21,900 shares of the firm’s stock in a transaction dated Thursday, January 21st. The stock was sold at an average price of $110.03, for a total value of $2,409,657.00. Following the completion of the sale, the chief executive officer now directly owns 141,442 shares in the company, valued at $15,562,863.26. The disclosure for this sale can be found here. Insiders have sold 49,094 shares of company stock worth $5,181,081 over the last ninety days. Insiders own 14.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of EBS. Riverview Trust Co bought a new stake in shares of Emergent BioSolutions in the fourth quarter worth about $30,000. Baillie Gifford & Co. bought a new stake in shares of Emergent BioSolutions in the fourth quarter worth about $36,000. Neo Ivy Capital Management grew its stake in shares of Emergent BioSolutions by 560.7% in the fourth quarter. Neo Ivy Capital Management now owns 403 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 342 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in shares of Emergent BioSolutions in the fourth quarter worth about $41,000. Finally, Point72 Hong Kong Ltd bought a new stake in shares of Emergent BioSolutions in the third quarter worth about $59,000. 80.23% of the stock is currently owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Further Reading: Exchange-Traded Funds (ETFs)

Analyst Recommendations for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.